The Rare Disease Action Forum (RDAF) held its annual General Assembly meeting on 28 March 2023. During the meeting, the RDAF Secretariat presented an overview of the...

13th International Rare Disease Day in Switzerland
The Rare Disease Action Forum supports the International Rare Disease Day, a globally coordinated movement that advocates for equal access to healthcare, treatments and diagnoses...
The RDAF organizes a webinar on early diagnosis for rare diseases in Switzerland
The Rare Disease Action Forum (RDAF) will host a multi-stakeholder webinar on ‘Early diagnosis for rare diseases’ on 29 March 2023, 17.00-18.30 CET. The webinar focuses on the...
RDAF December 2022 Newsletter
The RDAF is continuously active to raise awareness about rare diseases and improve patients’ access to diagnosis, treatment and care in Switzerland. Below are the highlights of...
Joint statement on the KVV/OAMal and KLV/OPAS revision
The RDAF co-signed a joint statement with other stakeholders on the revision of the Health Insurance Ordinance (KVV/OAMal) and Health Benefits Ordinance (KLV/OPAS). The statement...
The Rare Disease Action Forum (RDAF) advocates for a fair and rapid access to high-quality treatment for patients with rare diseases in Switzerland.
In line with this concern, the RDAF would like to draw attention to the fact that the planned revision of the Health Insurance Ordinance (KVV), contrary to its stated objective,...
RDAF position statement on KVV/KLV revision
The Rare Disease Action Forum has published a position paper in relation to the consultation organized by the Federal Office of Public Health on the revision of the Health...
The RDAF publishes its newsletter
The newsletter, which is published twice a year, gives an overview of all the Rare Disease Action Forum (RDAF) activities during the past half year to raise awareness about rare...
RDAF 2022 General Assembly Meeting
On 21 March 2022, the Rare Disease Action Forum (RDAF) held its annual General Assembly meeting. An overview of the RDAF’s activities in 2021 and an outlook for 2022 were...